Kornimate/medical-research-clean huggingface dataset:
a study to evaluate the clinical epidemiology of patients with heart failure (hf) in india

Conditions: Heart Failure

Summary: this non-interventional, prospective, multi-centric, cross-sectional study is aimed to observe clinical practice in india in managing heart failure patients \& to check one year outcome in hf patients. a total of 5 visits will be conducted during the study. there will be a baseline visit followed by four follow-up visits to assess the outcomes

a non-interventional, prospective study to evaluate the clinical epidemiology of patients with heart failure (hf) in india

Eligibility criteria:
inclusion criteria: 1. provision of subject informed consent 2. female or male aged 18 years and over 3. all patients with dyspnea and/or signs of systemic congestion exclusion criteria: 1. subjects with current acute coronary syndrome 2. absence of cardiac disease/structural heart disease

Keywords: heart failure cardiovascular disease congestive heart failure
mitoq for fatigue in multiple sclerosis (ms)

Conditions: Multiple Sclerosis; Fatigue

Summary: the purpose of this study is to determine whether ms patients who receive oral mitoquinone (mitoq) have less fatigue than those receiving a placebo. a comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if mitoq has a significant change in fatigue.

recruitment of subjects on hold due to covid-19 pandemic mitoq is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. while the cause of ms related fatigue is uncertain, the investigators believe that mitochondria dysfunction and resultant neuronal energy depletion may be an important contributor to fatigue in ms. this clinical trial will evaluate the potential beneficial effects of mitoq on ms fatigue. it will also explore the effects of mitoq on cognitive function, quality of life and mood. if enrolled in the study, patients will take two capsules of the study drug or placebo at the same time every day for twelve weeks. there will be 4 study visits where the participant will undergo medical and nervous system examinations, questionnaires, and blood draws. because it is a placebo-controlled trial, participants will have a 33% chance of receiving either placebo (inactive), 20mg of mitoq, or 40mg of mitoq. this will be a blinded randomized study, meaning neither the participant nor the investigator will know who received the placebo or study drug.

Eligibility criteria:
inclusion criteria: * ms (any clinical subtype) as diagnosed by the 2017 mcdonald criteria * edss score of 2 to 8 * complaint of fatigue that has been persistent for at least two months * modified fatigue impact scale (mfis) score of 38 or greater exclusion criteria: * treatment with systemic glucocorticoids in the prior six weeks * beck depression inventory (bdi) \>31 or bdi-fs\>10 (severe depression) * significant ms exacerbation in prior 30 days * previous use of mitoq or coenzyme q10 (coq10) within thirty days of screening appointment * other significant health problem that might increase risk of patient experiencing adverse events (aes), e.g.: * active coronary heart disease * liver disease * pulmonary disease * diabetes mellitus * pregnancy or intending to become pregnant or breastfeeding * unable to complete the self-report forms * unable to give informed consent * prisoners * any condition which would make the patient in the opinion of the investigator unsuitable for the study

Keywords: multiple sclerosis fatigue mitochondrial
clinical performance evaluation of the hativ p30

Conditions: Arrhythmia

Summary: hativ p30 is intended to record, store, and transfer one-and two-channel ecg rhythms, and analyze them based on an artificial intelligence (ai) algorithm. in single channel mode, hativ p30 can record lead-i. in two-channel mode, hativ p30 can record lead-i and lead-ii simultaneously and derive lead-iii and unipolar limb leads avr, avf and avl. the ecg signal measured through the device's electrode is converted into a digital signal and transmitted via bluetooth to an android or ios-based smart device with a mobile app installed. the ecg signal and analysis result can be checked through the screen of the smart device. the aim of this clinical study is to assess the safety and efficacy of the hativ p30 ecg recording device, as well as to gather data to support an fda submission through the 510(k) process for the device's commercialization.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older * able to provide written informed consent * able to remain in the same position for an ecg recording for at least 20 minutes using a standard 12-lead ecg recorder and the hativ p30 device * nsr cohort only: no history of arrhythmia * nsr cohort only: no history of cardiovascular diseases, including but not limited to hypertension, hyperlipidemia, coronary artery disease, heart failure, peripheral artery disease, and stroke * nsr cohort only: being in nsr at the time of screening ecg * arrhythmia cohort only: documented persistent, permanent, or chronic arrhythmia (af or flutter, sinus rhythm with apb, sinus rhythm with vpb) * arrhythmia cohort only: being in arrhythmia (af or flutter, sinus rhythm with apb, sinus rhythm with vpb) at the time of screening ecg exclusion criteria: * subjects with an implantable pacemaker device, implantable cardioverter-defibrillator device, or internal simulator that would generate internal interference with the recording of the hativ p30 device or a standard 12-lead ecg recorder * any medical or cognitive condition that would interfere with the consenting process and study-related procedures as determined by the investigator * any known clinical condition (e.g., body tremors, non-healed chest wound, limb absence, etc.) that would preclude appropriate placement of the leads and/or compromise study measurements in the opinion of the investigator * poor 12-lead screening ecg quality * pregnant at the time of enrollment * participation in other interventional clinical studies that includes active treatment for the last three (3) months (observational studies and long-term follow-up \[no active treatment\] will be allowed) * screening ecg record resulting in a significant arrhythmia out of the scope of the study, such as supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, neurocardiogenic syncope, among others
effects of a complete diet in critically ill patients with stress hyperglycemia

Conditions: Critical Illness; Hyperglycemia; Dietary Modification; Metabolic Stress Hyperglycemia; Mechanical Ventilation Complication

Summary: the aim of the study is to evaluate the beneficial effects of the administration of a complete diet rich in monounsaturated fatty acids (mufa) and slow absorption carbohydrate in patients with stress hyperglycemia(t-diet plus diabet ir). the main objective of this project is to evaluate blood glucose metabolic control, insulin requirements, insulin action resistance, lipid profile and to reduce infectious complications on mechanical ventilation icu (intensive care unit) patients after the administration of a complete diet enriched in mufa and slow absorption carbohydrates, without fructose.

enteral formula administration designed for critically ill patients in metabolic stress situations, hyperglycemia and insulin resistance, formulated with monounsaturated fatty acids (mufa), slowly absorption carbohydrates, omega-3 series polyunsaturated fatty acids (pufa)enriched in eicosapentanoic acid (epa) and docosahexaenoic acid (dha), should be associated with an improvement in metabolic control, based on glucose levels reduction, and a decrease of insulin resistance infectious complications , mechanical ventilation days, icu and hospital stay. all this against other two high protein conventional specific diets for hyperglycaemia patients.

Eligibility criteria:
inclusion criteria: * patients over 18 admitted to intensive care units (icu), with mechanical ventilation. * patients receiving en (enteral nutrition), for 5 days or more. * icu stay in 48 hours or less, in the time of study inclusion. * patients developing hyperglycemia in 48 hours of stay in icu. * nutritional support initiation within 48 hours of stay in icu. exclusion criteria: * patients with a life expectancy less than 48 hours. * patients participating in another study. * patients with apache ii (acute physiology and chronic health evaluation) less than 10. * patients with bmi (body mass index) \> 40 kg/m2. * patients with type i diabetes. * patients on chronic treatment with corticosteroid dose above 1 mg / kg / day of methylprednisolone or equivalent. * pregnant patients. * patients taking lipid-lowering drugs. * acute renal failure patients, defined by the following criteria: * serum creatinine greater than 4 mg / dl with acute rise higher than 0.5 mg / dl / day. * serum creatinine higher than 3 mg/dl. * diuresis \< 0.3 ml/kg/h during 24 hours. * anury for 12 hours or more. * hepatic failure patients, defined by the following parameters: * serious acute hepatic failure. * child degrees b-c. * serum bilirubin higher than 3 mg/dl. * patients with parenteral nutrition during study inclusion. * informed consent absence.

Keywords: critical illness hyperglycemia mechanical ventilation enteral nutrition t-diet plus diabet ir malnutrition insulin resistance metabolic stress
effectiveness of perturbations exercises in improving balance, function and mobility in stroke patients

Conditions: Stroke

Summary: following stroke, patients loses functions of the motor, sensory and higher brain cognitive faculties to various degrees which lead to diminished balance. it has been documented that hemiplegic or hemiparetic stroke patients presented with more posture sway, asymmetric weight distribution, impaired weight-shifting ability and decreased stability capability. there are many balance exercises and strategies; to improve balance in elderly age group population, to prevent fall prevention. but we have very few evidences of giving manual perturbation balance training in stroke patients to improve speed, balance and function. therefore this study is taken up to examine whether the manual perturbation balance training is more effective in improving speed, balance and function in stroke patients.

there are many more studies done for elderly populations, normal individuals for improving balance by giving perturbation based balance training.all perturbation exercises are given by either mechanical or by self reaching tasks in forward,backward,and in both sideways. there are very studies ;who attempted perturbation based balance training to improve balance in elderly population but not for stroke patients for their speed, balance and function.the manual perturbation exercise can be an promising intervention in the future for various conditions

Eligibility criteria:
inclusion criteria: 1. first ever stroke 2. age ranges between 40-70 3. both genders were included 4. ambulatory patients with or without ambulatory aids 5. occurrence of stroke at within 0-3 months i.e.-sub acute 6. able to follow command 7. mini mental scale examinations not less than 24 exclusion criteria: 1. patients who has severe limitations in passive range of motion at lower extremities 2. patients with impaired sensory, proprioceptor, cognitive and perceptual ability 3. patient who has contracture 4. orthopedic or any other neurological disorder which impair balance
a 52-week study to learn about the safety and effects of ritlecitinib in participants with nonsegmental vitiligo

Conditions: Vitiligo

Summary: this study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (nsv). ritlecitinib is studied in patients with non-segmental vitiligo. vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. non-segmental vitiligo is an autoimmune disorder and is the focus of this study. the study will show: * if the repigmentation (the recovery of pigmentation) achieved in study b7981040 (also called the "parent study") will stay the same or will further increase if you keep receiving the same study medicine (ritlecitinib 50 milligrams or placebo) * or if more repigmentation can be achieved if you start receiving ritlecitinib 100 milligrams in this study * or how long the repigmentation achieved during the parent study lasts if you start receiving placebo in this study. this study is seeking for participants who: * have non-segmental vitiligo (either active or stable) and * received ritlecitinib or placebo for 52 weeks in the parent study. a placebo looks exactly like the study capsule but does not contain any medicine in it. all participants in this study will receive the study medicine or placebo. the study medicine (ritlecitinib 50 milligrams or 100 milligrams) or placebo are capsules that are taken by mouth at home every day. at week 4 (or if it cannot be done then, at week 8) study visit, you must take the medication at the study site, and not at home. participants may receive the study medicine or placebo for up to 52 weeks. the study will look at the experiences of people receiving the study medicine. this will help see if ritlecitinib is better for treating vitiligo. participants will be involved in this study for a maximum of 60 weeks. during this time, they will have 9 study visits during the study. ritlecitinib 50 mg is an approved drug for the treatment of severe alopecia areata (a disease with similar abnormal changes in the body functions like vitiligo) in the us, eu and japan. china, great britain and other market applications are pending.


Eligibility criteria:
inclusion criteria: * participants ≥18 years of age at screening in study b7981040. adolescents (12 to \<18 years of age at screening in the parent study) are also eligible for this study if approved by the local irb/ec and regulatory health authority. * participants who met the eligibility criteria and completed 52 weeks of study intervention for stable or active nonsegmental vitiligo in study b7981040 * the bl visit/first dose in study b7981041 must be within 30 days after the week 52 visit in study b7981040 exclusion criteria: * participant met the parent study (study 7981040) discontinuation criteria or discontinued the parent study for any safety-related event * any active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation

Keywords: stable vitiligo active vitiligo adults adolescents
chronic fatigue etiology in intensive care unit survivors: the role of neuromuscular function

Conditions: Chronic Fatigue Syndrome; Intensive Care Unit; Muscle

Summary: chronic fatigue is the most common and debilitating symptom in intensive care unit (icu) survivors. indeed, it has been widely reported that patients who stayed in icu for prolonged periods report a feeling of tiredness for months to years after icu discharge. this chronic fatigue affects their quality of life by decreasing their capacity to perform simple tasks of daily life. the aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in this feeling of chronic fatigue. because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. a better knowledge of chronic fatigue etiology will allow to optimize rehabilitation treatments to decrease the apparition/persistence of chronic fatigue and in fine improve life quality.


Eligibility criteria:
inclusion criteria: * have been ventilated for at least 72 hours in the intensive care unit * igs2 score (severity in resuscitation) \> 15 * facit-f (functional assessment of chronic illness therapy-fatigue) score ≥ 36 or a score ≤ 32 * intensive care unit discharge in ≥ 6 months and ≤ 5 years preceding the study * approval received from a physician * command of the french language exclusion criteria: * taking neuroactive substances that can alter corticospinal excitability * contraindication to the application of a magnetic field * contraindication to the practice of magnetic resonance imaging * participant is pregnant * patients with psychiatric disorders * paraplegic and hemiplegic patients * addictive disorders

Keywords: neuromuscular function
the effect of percutaneous kirschner wire technique in management of cpt under one year old

Conditions: Congenital Pseudarthrosis of Tibia

Summary: the aim of this study was to investigate the effect of percutaneous kirschner wire in management of congenital pseudarthrosis of tibia in children younger than 1 year of age. this study was to determine the union rates of congenital pseudarthrosis in children operated before 1 year of age to identify growth abnormalities in the affected limb ,including ankle valgus,tibia valgus,and shortening.

currently, the timing of surgery for congenital pseudarthrosis of the tibia is a controversial issue. the investigators use percutaneous kirschner wire technique to manage the congenital pseudarthrosis of tibia in children younger than 1 year of age.to investigate the effect of percutaneous kirschner wire in management of congenital pseudarthrosis of tibia in children younger than 1 year of age. bone uion rate,average time of healing, ankle valgus, limb length discrepancy, tibia axis alignment are recorded and evaluated.

Eligibility criteria:
inclusion criteria: * all patients did not undergo procedures * patients with crawford type iv cpt treated with percutaneous kirschner wire techniques * the age during surgery was less than 12 months old exclusion criteria: * patients with pseudarthrosis of tibia caused by trauma,infection, etc

Keywords: congenital pseudarthrosis of the tibia age of surgery percutaneous kirschner wire
effect of massage treatment in temporomandibular joint

Conditions: Massage Therapy; Temporomandibular Disorder

Summary: temporomandibular disorders (tmd) have multiple and broad clinical effects on orofacial structures and are often diagnosed in patients with a prevalence of between 5% and 12%. among treatment options, massage therapy is one of the common therapeutic procedures and allows interesting clinical outcomes by reducing tmd symptoms successfully. however, there has been no attempt to validate this knowledge. thus, the aim of this study is to evaluate the effect of massage and its properties in patients with tmd.


Eligibility criteria:
inclusion criteria: 1. temporomandibular disorder-positive rdc/tmd examination for groups rdc/tmd ia and rdc/tmd ib, 2. patient agreement to participate in the experimental study. exclusion criteria: 1. rdc/tmd ii and rdc/tmdiii, 2. drug and/or removable partial or total prosthesis wearers, 3. being submitted to any type of physiotherapeutic treatment, 4. incomplete dentition, 5. history of systemic diseases as diabetes or arthritis, 6. the occurrence of facial trauma, 7. refusal to assume responsibility with this research.

Keywords: massage
outcome after lumbar epidural steroid injection

Conditions: Disc Disease

Summary: prospectively validate a fibronectin-aggrecan complex as a biomarker for response to esi for radiculopathy with hnp

we will measure levels of the protein complex in the epidural space of patients undergoing lumbar esi for radiculopathy with hnp. we assess functional outcomes at baseline and after treatment with the medical outcomes study short form-36 instrument (sf-36). our hypothesis was that the complex is present in patients with clinically significant functional improvement after esi.

Eligibility criteria:
inclusion criteria: * acute onset of sensory symptoms with the primary complaint as pain as well as varying sensory symptoms (e.g. tingling, numbness) in one or more lumbar nerve root distributions * positive physical exam findings including sensory findings consistent with a spinal nerve root, a positive straight leg raise test, and/or a diminished patellar or achilles dtr consistent with sensory symptoms; and * mri of lumbar spine positive for hnp in a distribution correlating with physical examination exclusion criteria: * plain radiography demonstrating severe loss of disc height, high grade ddd, spondylolisthesis greater than grade i * a history of prior lumbar surgery or trauma, weakness in a consistent distribution (non-progressive with strength at least 4/5) * red flags including progressive weakness, bowel/bladder complaints, radiographic unknown mass, unexpected weight loss; and * diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases

Keywords: biomarker epidural steroid radiculopathy hnp
increased early pain relief by adding vertebroplasty to sbrt

Conditions: Spine Metastases; Radiation Therapy; Pain

Summary: the goal of treating metastases is to preserve stability and neurological function while reducing pain. the actual standard of care is stereotaxic body radiation therapy (sbrt) alone in non-surgical patients. the added value of vertebroplasty to sbrt is not well documented in the literature, nor whether performing vertebroplasty before radiotherapy treatment leads to a reduction in the rate of fractures and post-sbrt pain.


Eligibility criteria:
inclusion criteria: * histological evidence of cancer. * spinal and vertebral bone metastases (t5 to l5) documented by imaging. * pain related to metastases ≥ 4 on a numerical scale 0-10. * karnofsky performance index \> 60 (ecog 0-2) * candidate for sbrt * less than 3 consecutive levels reached. * ability to complete follow-up questionnaires regarding pain, analgesics, and quality of life assessment. * potentially unstable lesions according to the spinal instability neoplastic score (sins) scale (\> or = 7) exclusion criteria: * pregnancy or breastfeeding. * contraindications to mri. * histology: myeloma, lymphoma or plasmacytoma. * radiotherapy prior to the level to be treated. * previous surgery at the site to be treated. * surgical indication: spinal instability neoplastic score (sins) \> 13 or according to tumor board consensus. bilsky score \> or = 2 severe or progressive neurological signs (motor, incontinence). * lesion too large for safe vertebroplasty. * high thoracic location not allowing safe visibility in fluoroscopy to perform vertebroplasty (t4 and above). * non-reversible coagulation disorders. * uncontrolled local or systemic infection. * estimated survival of less than 6 months. * inability or refusal to undergo sbrt treatment or vertebroplasty